1) Validates use of Human-on-a-Chip system to mimic disease mechanisms of rare autoimmune neuropathies that cannot be replicated in animal models.
2) Efficacy data from microphysiological system supported the authorization of a clinical study (NCT04658472) in 2021 through collaboration with Sanofi.
Hesperos, Inc is proud to announce Dr. Virginia Smith’s recent publication in Frontiers in Cell and Developmental Biology which validates the Human-on-a-Chip method to model the rare autoimmune disease, Myasthenia Gravis. Read the full press release below: … Read More
Hesperos and Tabula Rasa receive $1.9M National Institutes of Health Research Grant Focused on Preventable Drug-Induced Alzheimer’s Disease
New study published in Nature Scientific Reports validates the utility of Human-on-a-Chip to model Nonalcoholic Fatty Liver Disease (NAFLD)
Senior Editor with Pharma Manufacturing interviews Hesperos executives Michael Shuler and Nathan Post on the rise of Human-on-a-Chip (HoaC) systems and how they are replacing the need for animal testing in drug discovery.
We have set out on a journey to change the drug development process for the better so patients can get the treatments they desperately need and not have to wait years for them to become available. … Read More